PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate headache score and accompanying symptoms during and after infusion of PACAP38 i migraine patients

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Headache Center
• Treatments: Pituitary Adenylate Cyclase-Activating Polypeptide

Criteria

Inclusion Criteria:

• Healthy migraine patient without aura

• Aged 18-50

• 50-100 kg

• Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.

Exclusion Criteria:

• Tension type headache more than five times/month

• Other primary headaches

• Daily medication except contraceptives

• Drug taken within 4 times the halflife for the specific drug except contraceptives

• Pregnant or lactating women

• Exposure to radiation within the last year

• Headache within the last 48 hours before start of trial

• Hypertension

• Hypotension

• Respiratory or cardiac disease